NO20050450L - Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft - Google Patents
Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreftInfo
- Publication number
- NO20050450L NO20050450L NO20050450A NO20050450A NO20050450L NO 20050450 L NO20050450 L NO 20050450L NO 20050450 A NO20050450 A NO 20050450A NO 20050450 A NO20050450 A NO 20050450A NO 20050450 L NO20050450 L NO 20050450L
- Authority
- NO
- Norway
- Prior art keywords
- combination
- cancer
- radiotherapy
- inhibitor
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 108091008605 VEGF receptors Proteins 0.000 title 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000001959 radiotherapy Methods 0.000 title 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000005865 ionizing radiation Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0218525A GB0218525D0 (en) | 2002-08-09 | 2002-08-09 | Combination therapy |
| GB0307560A GB0307560D0 (en) | 2003-04-02 | 2003-04-02 | Combination therapy |
| PCT/GB2003/003388 WO2004014383A1 (en) | 2002-08-09 | 2003-08-05 | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20050450L true NO20050450L (no) | 2005-05-02 |
Family
ID=31716921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050450A NO20050450L (no) | 2002-08-09 | 2005-01-26 | Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050222183A1 (enExample) |
| EP (1) | EP1534287A1 (enExample) |
| JP (1) | JP2006502132A (enExample) |
| KR (1) | KR20050056190A (enExample) |
| CN (1) | CN1313094C (enExample) |
| AU (1) | AU2003249000B2 (enExample) |
| BR (1) | BR0313116A (enExample) |
| CA (1) | CA2495487A1 (enExample) |
| IL (1) | IL166522A0 (enExample) |
| MX (1) | MXPA05001458A (enExample) |
| NO (1) | NO20050450L (enExample) |
| NZ (1) | NZ537753A (enExample) |
| WO (1) | WO2004014383A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1244647E (pt) * | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| IL151626A0 (en) | 2000-04-07 | 2003-04-10 | Astrazeneca Ab | Quinazoline compounds |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| EP2292615A1 (en) * | 2002-02-01 | 2011-03-09 | AstraZeneca AB | Quinazoline compounds |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
| DE602004032310D1 (de) * | 2003-02-13 | 2011-06-01 | Astrazeneca Ab | Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11 |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| JP2007526886A (ja) * | 2003-07-10 | 2007-09-20 | アストラゼネカ アクチボラグ | 血管新生および／または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体ｚｄ６４７４の使用 |
| KR20070072543A (ko) * | 2004-09-27 | 2007-07-04 | 아스트라제네카 아베 | Ｚｄ6474 및 이마티닙을 포함하는 병합법 |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
| CA2631764A1 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Combination of zd6474 and pemetrexed |
| JP4945133B2 (ja) * | 2006-01-19 | 2012-06-06 | 富士フイルムＲｉファーマ株式会社 | ４−フェノキシキナゾリン誘導体放射性化合物 |
| WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
| US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
| WO2009118560A1 (en) * | 2008-03-28 | 2009-10-01 | Astrazeneca Ab | Combination therapy 038 |
| CN106317022A (zh) * | 2015-06-25 | 2017-01-11 | 中美华世通生物医药科技（武汉）有限公司 | 化合物的制备方法和用途 |
| CN106397401B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种抗癌药物的晶体化合物及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1244647E (pt) * | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
-
2003
- 2003-08-05 AU AU2003249000A patent/AU2003249000B2/en not_active Ceased
- 2003-08-05 EP EP03784247A patent/EP1534287A1/en not_active Withdrawn
- 2003-08-05 MX MXPA05001458A patent/MXPA05001458A/es unknown
- 2003-08-05 CN CNB038191016A patent/CN1313094C/zh not_active Expired - Fee Related
- 2003-08-05 CA CA002495487A patent/CA2495487A1/en not_active Abandoned
- 2003-08-05 WO PCT/GB2003/003388 patent/WO2004014383A1/en not_active Ceased
- 2003-08-05 US US10/523,832 patent/US20050222183A1/en not_active Abandoned
- 2003-08-05 KR KR1020057002082A patent/KR20050056190A/ko not_active Ceased
- 2003-08-05 NZ NZ537753A patent/NZ537753A/en unknown
- 2003-08-05 JP JP2004527017A patent/JP2006502132A/ja active Pending
- 2003-08-05 BR BR0313116-5A patent/BR0313116A/pt not_active IP Right Cessation
-
2005
- 2005-01-26 IL IL16652205A patent/IL166522A0/xx unknown
- 2005-01-26 NO NO20050450A patent/NO20050450L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003249000A1 (en) | 2004-02-25 |
| US20050222183A1 (en) | 2005-10-06 |
| CA2495487A1 (en) | 2004-02-19 |
| EP1534287A1 (en) | 2005-06-01 |
| WO2004014383A1 (en) | 2004-02-19 |
| IL166522A0 (en) | 2006-01-15 |
| JP2006502132A (ja) | 2006-01-19 |
| KR20050056190A (ko) | 2005-06-14 |
| CN1674905A (zh) | 2005-09-28 |
| MXPA05001458A (es) | 2005-06-06 |
| CN1313094C (zh) | 2007-05-02 |
| NZ537753A (en) | 2008-04-30 |
| AU2003249000B2 (en) | 2007-04-05 |
| BR0313116A (pt) | 2005-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
| DK1551409T3 (da) | Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer | |
| NO20060307L (no) | Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet | |
| DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
| CY1111565T1 (el) | Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11 | |
| NO20072167L (no) | Kombinasjon omfattende ZD6474 og et antiandrogen | |
| NO20050528L (no) | Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft | |
| NO20071428L (no) | Kombinasjon inneholdende ZD6474 og Imatinib | |
| AR037346A1 (es) | Terapia de combinacion | |
| DE602004022285D1 (de) | Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika | |
| DE602004011051D1 (de) | Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten | |
| ATE500832T1 (de) | Kombination von zd6474 und pemetrexed | |
| NO20076657L (no) | Kombinasjonsterapi av cancer med AZD2171 og gemcitabin | |
| NO20056170L (no) | Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839 | |
| NO20064753L (no) | Kombinasjonsterapi | |
| DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| MXPA05013827A (es) | Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g. | |
| NO20051601L (no) | Kombinasjonsterapi med gemcitabin og zd6126 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |